<DOC>
	<DOCNO>NCT00000774</DOCNO>
	<brief_summary>PRIMARY : To determine safety envelope recombinant proteins rgp120/HIV-1MN ( Genentech ) rgp120/HIV-1SF2 ( Chiron/Biocine ) infant indeterminate HIV status bear HIV-infected woman . To evaluate change viral load infant proven infect absolute CD4 count immunized infant . SECONDARY : To evaluate immunogenicity envelope recombinant proteins infant indeterminate HIV status bear HIV-infected woman . Only 30-50 percent HIV-infected infant detectable virus birth . Successful early sensitization HIV envelope epitope may help prevent infection , alternatively , may enhance HIV-specific immune function alter HIV replication disease progression .</brief_summary>
	<brief_title>A Phase I Study Evaluate Safety Immunogenicity Recombinant HIV-1 Envelope Antigen Children Born HIV-Infected Mothers</brief_title>
	<detailed_description>Only 30-50 percent HIV-infected infant detectable virus birth . Successful early sensitization HIV envelope epitope may help prevent infection , alternatively , may enhance HIV-specific immune function alter HIV replication disease progression . Newborns randomize one three different dos either rgp120/HIV-1MN rgp120/HIV-1SF2 matching placebo . At dose level , 12 patient receive vaccine three patient receive placebo . Immunizations perform 0 , 4 , 12 , 20 week , patient follow 2 year age . Three four patient treat give dose level must receive two immunization without evidence grade 3 4 clinical laboratory toxicity dose escalation occurs . Twelve additional patient treat optimal dose vaccine week 0 , 2 , 8 , 20 ( An accelerate schedule PER AMENDMENT 3/20/96 . Changed - 0 , 4 , 8 , 20 ) accompany three additional placebo patient per vaccine . PER AMENDMENT 3/20/96 : The optimal dose rgp120/HIV-1MN 100 mcg give 12 patient placebo give 3 . The optimal dose rgp120/HIV-1SF2 5 mcg give 12 patient placebo give 3 . PER 2/3/95 AMENDMENT : After initial patient enrol , 18 additional newborn randomize one three dose level rgp120/HIV-1MN ( placebo ) . PER AMENDMENT 6/5/95 : Another group 18 newborn randomize one three treatment represent 3 different dos Chiron/Biocine vaccine ( placebo ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy . Coenrollment therapeutic protocol begin least 30 day follow week 20 immunization . Routine immunization give 1 week study vaccine . Patients must : &gt; 37 week gestation &lt; 72 hour age bear HIVinfected woman . NOT born woman receive either passive active immunotherapy pregnancy . NOT breastfed . NOT born woman hepatitis B surface antigen positive . Receiving AZT study entry ( except infant enrol ACTG 076 ) . NOTE : Parent guardian must provide informed consent willing comply study requirement . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Documented suspect serious bacterial infection , metabolic illness , immediate lifethreatening condition . Concurrent Medication : Excluded : Passive active HIVspecific immunotherapy study candidate vaccine . Investigational medication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Days</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Vaccines , Synthetic</keyword>
	<keyword>Virus Replication</keyword>
	<keyword>HIV Envelope Protein gp120</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>